Access investment opportunities like the big end of town.

A revenue-generating regenerative medicine and 3D bioprinting company

Koligo Therapeutics Ltd (ASX: KOL) is a US biotechnology company focused on the development and commercialisation of a range of cell therapy, three-dimensional (3D) bioprinted tissue and other regenerative medicine products for serious unmet medical needs.  Koligo has successfully commercialised and has commenced selling its first cell therapy transplant product, Kyslecel™, for the treatment of chronic pancreatitis patients, generating $1.6 million in revenue from sales of this product. Koligo is also working on other transformative cell therapies for a range of indications, including type 1 diabetes, and other pancreatic diseases.

Global software provider in the digitisation and automation of asset processing and reporting solutions.

 Offer closed via OnMarket.

AXS Group Limited (ASX Code: AXS) is an integrated software solution provider to the finance, insurance and funds sector. With over 40 clients in Australia, North America, Europe and Asia they are focussed on helping clients with their digital transformation, reducing time and cutting costs. The Company’s cloud based ARMnet platform currently is used to manage over $100 billion of assets and transactions that are accessible via smart phones, tablets or email from anywhere at any time.

Developing, sourcing and branding high quality Australian made milk formula and nutrition products

Offer closed early via OnMarket.  Payments are now due by 5pm Friday 22 March.

Australian Nutrition & Sports Ltd (ASX: AN1) is focussed on the development, branding and distribution of its own high-quality milk formula, health and wellness products for sale in Australia, China, Hong Kong, with plans to expand into further Asian markets over time.  Currently focused on infant and adult milk formula products,  protein-based health and wellness nutritional supplements, the company has successfully commercialised a number of products in Hong Kong with distribution through ~350 pharmacies. Expansion into the Chinese market is supported by production agreements with export approved Australian manufacturers.